Audio link is not working for me right now. Notic
Post# of 154370
(Total Views: 313)
Posted On: 07/10/2019 9:07:35 AM
Audio link is not working for me right now. Notice the investorshangout comment at the end 
PHOENIX, AZ / ACCESSWIRE / July 10, 2019 / The Stock Day Podcast welcomed CytoDyn (CYDY) (“the Company”), a biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CEO and President, Nader Pourhassan, Ph.D., joined Stock Day host Everett Jolly.
Jolly began the interview by asking about the Company’s recent press release regarding a new addition to their team. Dr. Pourhassan explained that Dr. Jonah Sacha has been named the Company’s Senior Science Advisor and adds extensive experience in HIV research to the team. Dr. Sacha will be exploring leronlimab (PRO 140) for its potential use in HIV prevention.
Dr. Pourhassan also explained that the Company will be exploring possible cures for HIV with the help of Dr. Sacha, and based on vast data from monotherapy clinical trial, they are confident in their abilities for this project.
Jolly then asked Dr. Pourhassan to share more information about the Company’s preventative treatments for HIV. Dr. Pourhassan explained that the Company is close to developing a preventative treatment using the antibody, leronlimab (PRO 140), which works to prevent HIV from entering T-cells. “That is a very powerful concept,” explained Dr. Pourhassan.
Jolly followed by asking about the Company’s BLA (Biologics License Application). Dr. Pourhassan explained that the Company is still in the process of filing the rest of their BLA to the FDA, however, the outcome is looking positive. He explained that the Company might be able to complete their BLA by the end of August 2019 for clinical and end of September 2019 for their manufacturing, which makes achieving final approval by next year, first or second quarter very possible.
Jolly then asked about the Company’s strategy for revenue. Dr. Pourhassan explained that raising the necessary funds and receiving FDA approval for their treatments are key to having revenue. “The strategy is to make sure we stand strong at this point,” stated Dr. Pourhassan. He added that having revenue is not too far from us and will represent a significant step for our shareholders.
To hear Dr. Pourhassan’s entire interview, follow the link to the podcast here:
https://audioboom.com/posts/7311681-the-stock...their-team
Investors Hangout is a proud sponsor of “Stock Day,” and Stock Day Media encourages listeners to visit the company’s message board at https://investorshangout.com/
PHOENIX, AZ / ACCESSWIRE / July 10, 2019 / The Stock Day Podcast welcomed CytoDyn (CYDY) (“the Company”), a biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CEO and President, Nader Pourhassan, Ph.D., joined Stock Day host Everett Jolly.
Jolly began the interview by asking about the Company’s recent press release regarding a new addition to their team. Dr. Pourhassan explained that Dr. Jonah Sacha has been named the Company’s Senior Science Advisor and adds extensive experience in HIV research to the team. Dr. Sacha will be exploring leronlimab (PRO 140) for its potential use in HIV prevention.
Dr. Pourhassan also explained that the Company will be exploring possible cures for HIV with the help of Dr. Sacha, and based on vast data from monotherapy clinical trial, they are confident in their abilities for this project.
Jolly then asked Dr. Pourhassan to share more information about the Company’s preventative treatments for HIV. Dr. Pourhassan explained that the Company is close to developing a preventative treatment using the antibody, leronlimab (PRO 140), which works to prevent HIV from entering T-cells. “That is a very powerful concept,” explained Dr. Pourhassan.
Jolly followed by asking about the Company’s BLA (Biologics License Application). Dr. Pourhassan explained that the Company is still in the process of filing the rest of their BLA to the FDA, however, the outcome is looking positive. He explained that the Company might be able to complete their BLA by the end of August 2019 for clinical and end of September 2019 for their manufacturing, which makes achieving final approval by next year, first or second quarter very possible.
Jolly then asked about the Company’s strategy for revenue. Dr. Pourhassan explained that raising the necessary funds and receiving FDA approval for their treatments are key to having revenue. “The strategy is to make sure we stand strong at this point,” stated Dr. Pourhassan. He added that having revenue is not too far from us and will represent a significant step for our shareholders.
To hear Dr. Pourhassan’s entire interview, follow the link to the podcast here:
https://audioboom.com/posts/7311681-the-stock...their-team
Investors Hangout is a proud sponsor of “Stock Day,” and Stock Day Media encourages listeners to visit the company’s message board at https://investorshangout.com/
(0)
(0)